# Rosetta Exosome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rosetta-exosome

- Industry: Biotechnology
- Headquarters: Gyeonggi-do, South Korea
- Website: www.rosettaexosome.com
- Total disclosed funding: $7.2M
- Latest round: Series A (Apr 27, 2021)
- Investors on record: 4

## About

Based in Gyeonggi-do, South Korea, and founded in 2016 by co-founders Yong Shong and Kwang Pyo Kim, Rosetta Exosome Inc. operates as a developer of proprietary and integrated next-generation platform technologies for the development of innovative exosome-based diagnostics and therapeutics against intractable diseases. In April 2021, Rosetta Exosome Inc. raised KRW 8 billion in series A funding led by investors DA Value Investment, with participation from other investors K Bridge Investment, Innopolis Partners, and DS & Partners.

The company offers the ExoLutE Exosome Isolation Kit, an ultracentrifugation-reproducible next-generation technology for extracellular vesicle isolation from mammalian cell-conditioned medium and biological fluids. The technology enables the mass production of exosomes from microorganisms other than human-derived stem cells, increasing the possibility of developing therapeutics using exosomes.

## Funding rounds

- Series A, Apr 27, 2021, $7.2M — Innopolis Partners, DS & Partners, DA Value Investment, K Bridge Ventures

## Investors

- Innopolis Partners (https://capitalatlas.ai/funds/innopolis-partners) — Series A
- DS & Partners (https://capitalatlas.ai/funds/ds-partners) — Series A
- DA Value Investment (https://capitalatlas.ai/funds/da-value-investment) — Series A
- K Bridge Ventures — Series A